298 related articles for article (PubMed ID: 17309955)
1. Nitroxyl anion donor, Angeli's salt, does not develop tolerance in rat isolated aortae.
Irvine JC; Favaloro JL; Widdop RE; Kemp-Harper BK
Hypertension; 2007 Apr; 49(4):885-92. PubMed ID: 17309955
[TBL] [Abstract][Full Text] [Related]
2. Chronic administration of the HNO donor Angeli's salt does not lead to tolerance, cross-tolerance, or endothelial dysfunction: comparison with GTN and DEA/NO.
Irvine JC; Kemp-Harper BK; Widdop RE
Antioxid Redox Signal; 2011 May; 14(9):1615-24. PubMed ID: 20849324
[TBL] [Abstract][Full Text] [Related]
3. Nitroxyl: a vasodilator of human vessels that is not susceptible to tolerance.
Andrews KL; Lumsden NG; Farry J; Jefferis AM; Kemp-Harper BK; Chin-Dusting JP
Clin Sci (Lond); 2015 Jul; 129(2):179-87. PubMed ID: 25728899
[TBL] [Abstract][Full Text] [Related]
4. NO- activates soluble guanylate cyclase and Kv channels to vasodilate resistance arteries.
Irvine JC; Favaloro JL; Kemp-Harper BK
Hypertension; 2003 Jun; 41(6):1301-7. PubMed ID: 12743008
[TBL] [Abstract][Full Text] [Related]
5. Redox variants of NO (NO{middle dot} and HNO) elicit vasorelaxation of resistance arteries via distinct mechanisms.
Favaloro JL; Kemp-Harper BK
Am J Physiol Heart Circ Physiol; 2009 May; 296(5):H1274-80. PubMed ID: 19252101
[TBL] [Abstract][Full Text] [Related]
6. Nitroxyl donors retain their depressor effects in hypertension.
Irvine JC; Ravi RM; Kemp-Harper BK; Widdop RE
Am J Physiol Heart Circ Physiol; 2013 Sep; 305(6):H939-45. PubMed ID: 23851276
[TBL] [Abstract][Full Text] [Related]
7. The concomitant coronary vasodilator and positive inotropic actions of the nitroxyl donor Angeli's salt in the intact rat heart: contribution of soluble guanylyl cyclase-dependent and -independent mechanisms.
Chin KY; Qin C; Cao N; Kemp-Harper BK; Woodman OL; Ritchie RH
Br J Pharmacol; 2014 Apr; 171(7):1722-34. PubMed ID: 24372173
[TBL] [Abstract][Full Text] [Related]
8. The nitroxyl anion (HNO) is a potent dilator of rat coronary vasculature.
Favaloro JL; Kemp-Harper BK
Cardiovasc Res; 2007 Feb; 73(3):587-96. PubMed ID: 17189622
[TBL] [Abstract][Full Text] [Related]
9. HNO/cGMP-dependent antihypertrophic actions of isopropylamine-NONOate in neonatal rat cardiomyocytes: potential therapeutic advantages of HNO over NO.
Irvine JC; Cao N; Gossain S; Alexander AE; Love JE; Qin C; Horowitz JD; Kemp-Harper BK; Ritchie RH
Am J Physiol Heart Circ Physiol; 2013 Aug; 305(3):H365-77. PubMed ID: 23729209
[TBL] [Abstract][Full Text] [Related]
10. Actions of Angeli's salt, a nitroxyl (HNO) donor, on ion transport across mucosa-submucosa preparations from rat distal colon.
Pouokam E; Bell A; Diener M
Eur J Pharmacol; 2013 Sep; 715(1-3):133-41. PubMed ID: 23747594
[TBL] [Abstract][Full Text] [Related]
11. Angeli's Salt, a nitroxyl anion donor, reverses endothelin-1 mediated vascular dysfunction in murine aorta.
Wynne BM; Labazi H; Carneiro ZN; Tostes RC; Webb RC
Eur J Pharmacol; 2017 Nov; 814():294-301. PubMed ID: 28830679
[TBL] [Abstract][Full Text] [Related]
12. The HNO donor Angeli's salt offers potential haemodynamic advantages over NO or dobutamine in ischaemia-reperfusion injury in the rat heart ex vivo.
Chin KY; Michel L; Qin CX; Cao N; Woodman OL; Ritchie RH
Pharmacol Res; 2016 Feb; 104():165-75. PubMed ID: 26747404
[TBL] [Abstract][Full Text] [Related]
13. Cardioprotective actions of nitroxyl donor Angeli's salt are preserved in the diabetic heart and vasculature in the face of nitric oxide resistance.
Velagic A; Li JC; Qin CX; Li M; Deo M; Marshall SA; Anderson D; Woodman OL; Horowitz JD; Kemp-Harper BK; Ritchie RH
Br J Pharmacol; 2022 Aug; 179(16):4117-4135. PubMed ID: 35365882
[TBL] [Abstract][Full Text] [Related]
14. Effects of agents that inactivate free radical NO (NO*) on nitroxyl anion-mediated relaxations, and on the detection of NO* released from the nitroxyl anion donor Angeli's salt.
Ellis A; Lu H; Li CG; Rand MJ
Br J Pharmacol; 2001 Oct; 134(3):521-8. PubMed ID: 11588105
[TBL] [Abstract][Full Text] [Related]
15. Vasorelaxant and antiaggregatory actions of the nitroxyl donor isopropylamine NONOate are maintained in hypercholesterolemia.
Bullen ML; Miller AA; Dharmarajah J; Drummond GR; Sobey CG; Kemp-Harper BK
Am J Physiol Heart Circ Physiol; 2011 Oct; 301(4):H1405-14. PubMed ID: 21803947
[TBL] [Abstract][Full Text] [Related]
16. Effects of the flavoprotein inhibitor, diphenyleneiodonium sulfate, on ex vivo organic nitrate tolerance in the rat.
Ratz JD; McGuire JJ; Anderson DJ; Bennett BM
J Pharmacol Exp Ther; 2000 May; 293(2):569-77. PubMed ID: 10773030
[TBL] [Abstract][Full Text] [Related]
17. A role for nitroxyl (HNO) as an endothelium-derived relaxing and hyperpolarizing factor in resistance arteries.
Andrews KL; Irvine JC; Tare M; Apostolopoulos J; Favaloro JL; Triggle CR; Kemp-Harper BK
Br J Pharmacol; 2009 Jun; 157(4):540-50. PubMed ID: 19338582
[TBL] [Abstract][Full Text] [Related]
18. Aorta from angiotensin II hypertensive mice exhibit preserved nitroxyl anion mediated relaxation responses.
Wynne BM; Labazi H; Tostes RC; Webb RC
Pharmacol Res; 2012 Jan; 65(1):41-7. PubMed ID: 21767645
[TBL] [Abstract][Full Text] [Related]
19. Does nitric oxide mediate the vasodilator activity of nitroglycerin?
Kleschyov AL; Oelze M; Daiber A; Huang Y; Mollnau H; Schulz E; Sydow K; Fichtlscherer B; Mülsch A; Münzel T
Circ Res; 2003 Oct; 93(9):e104-12. PubMed ID: 14551241
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological characterization of 1-nitrosocyclohexyl acetate, a long-acting nitroxyl donor that shows vasorelaxant and antiaggregatory effects.
Donzelli S; Fischer G; King BS; Niemann C; DuMond JF; Heeren J; Wieboldt H; Baldus S; Gerloff C; Eschenhagen T; Carrier L; Böger RH; Espey MG
J Pharmacol Exp Ther; 2013 Feb; 344(2):339-47. PubMed ID: 23211362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
